BACKGROUND AND PURPOSE: Nebivolol is a highly selective beta(1)-adrenoceptor antagonist with beta(3)-adrenoceptor agonist properties and is a racemate mixture of D- and L-enantiomers. However, the cellular mechanisms of the effects of each enantiomer are not yet clear and are a matter for debate. The aim of the present experiments was to determine the adrenoceptors involved in the vascular effects of D- and L-enantiomers of nebivolol in rat thoracic aorta. EXPERIMENTAL APPROACH: Responses to nebivolol enantiomers were evaluated in rings of thoracic aorta from male Sprague-Dawley rats. KEY RESULTS: D-nebivolol (0.1-10 micromol.L(-1)), but not L-nebivolol, significantly shifted to the right the concentration-response curve to phenylephrine, an alpha(1)-adrenoceptor agonist, in a concentration-dependent manner. For the following experiments, aortic rings were constricted with endothelin 1 and now both enantiomers produced an endothelium-dependent relaxation of the rings involving the nitric oxide pathway. This relaxation was not modified by 1 micromol.L(-1) CGP 20,712A (beta(1)-adrenoceptor antagonist), but significantly blunted by 7 micromol.L(-1) L-74,8337 (beta(3)-adrenoceptor antagonist). However, only the vasorelaxation induced by D-nebivolol was significantly reduced by 1 micromol.L(-1) ICI 118,551 (beta(2)-adrenoceptor antagonist). CONCLUSIONS AND IMPLICATIONS: Our results suggest that the nebivolol enantiomers act on different targets. D-nebivolol induced vasorelaxation by activating beta(2)- and beta(3)-adrenoceptors and antagonizing alpha(1)-adrenoceptors. L-nebivolol induced vasorelaxation by activating only beta(3)-adrenoceptors in our model. Our results emphasize that nebivolol is a beta(1)-adrenoceptor antagonist with several important pharmacological differences from other beta(1)-adrenoceptor antagonists.
BACKGROUND AND PURPOSE:Nebivolol is a highly selective beta(1)-adrenoceptor antagonist with beta(3)-adrenoceptor agonist properties and is a racemate mixture of D- and L-enantiomers. However, the cellular mechanisms of the effects of each enantiomer are not yet clear and are a matter for debate. The aim of the present experiments was to determine the adrenoceptors involved in the vascular effects of D- and L-enantiomers of nebivolol in rat thoracic aorta. EXPERIMENTAL APPROACH: Responses to nebivolol enantiomers were evaluated in rings of thoracic aorta from male Sprague-Dawley rats. KEY RESULTS:D-nebivolol (0.1-10 micromol.L(-1)), but not L-nebivolol, significantly shifted to the right the concentration-response curve to phenylephrine, an alpha(1)-adrenoceptor agonist, in a concentration-dependent manner. For the following experiments, aortic rings were constricted with endothelin 1 and now both enantiomers produced an endothelium-dependent relaxation of the rings involving the nitric oxide pathway. This relaxation was not modified by 1 micromol.L(-1) CGP 20,712A (beta(1)-adrenoceptor antagonist), but significantly blunted by 7 micromol.L(-1) L-74,8337 (beta(3)-adrenoceptor antagonist). However, only the vasorelaxation induced by D-nebivolol was significantly reduced by 1 micromol.L(-1) ICI 118,551 (beta(2)-adrenoceptor antagonist). CONCLUSIONS AND IMPLICATIONS: Our results suggest that the nebivolol enantiomers act on different targets. D-nebivolol induced vasorelaxation by activating beta(2)- and beta(3)-adrenoceptors and antagonizing alpha(1)-adrenoceptors. L-nebivolol induced vasorelaxation by activating only beta(3)-adrenoceptors in our model. Our results emphasize that nebivolol is a beta(1)-adrenoceptor antagonist with several important pharmacological differences from other beta(1)-adrenoceptor antagonists.
Authors: M A Broeders; P A Doevendans; B C Bekkers; R Bronsaer; E van Gorsel; J W Heemskerk; M G Egbrink; E van Breda; R S Reneman; R van Der Zee Journal: Circulation Date: 2000-08-08 Impact factor: 29.690
Authors: Dennis Ladage; Klara Brixius; Heike Hoyer; Caroline Steingen; Andreas Wesseling; Daniela Malan; Wilhelm Bloch; Robert H G Schwinger Journal: Clin Exp Pharmacol Physiol Date: 2006-08 Impact factor: 2.557
Authors: R Preston Mason; Ruslan Kubant; Robert F Jacob; Mary F Walter; Bohdan Boychuk; Tadeusz Malinski Journal: J Cardiovasc Pharmacol Date: 2006-07 Impact factor: 3.105
Authors: Juan P Aragón; Marah E Condit; Shashi Bhushan; Benjamin L Predmore; Sandeep S Patel; D Bennett Grinsfelder; Susheel Gundewar; Saurabh Jha; John W Calvert; Lili A Barouch; Madhav Lavu; Harold M Wright; David J Lefer Journal: J Am Coll Cardiol Date: 2011-12-13 Impact factor: 24.094
Authors: Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen Journal: Br J Clin Pharmacol Date: 2015-06-05 Impact factor: 4.335
Authors: Thomas Dupas; Thomas Pelé; Justine Dhot; Mélanie Burban; Antoine Persello; Virginie Aillerie; Angélique Erraud; Angela Tesse; David Stevant; Angélique Blangy-Letheule; Céline Menguy; Vincent Sauzeau; Michel De Waard; Bertrand Rozec; Chantal Gauthier; Benjamin Lauzier Journal: Oxid Med Cell Longev Date: 2022-05-18 Impact factor: 7.310